Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 6:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 356 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Metastases to Bone Clear all
Completed Phase 1Phase 2 Interventional

Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation

NCT00089037
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
methotrexate, sirolimus, tacrolimus
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 14, 2011 · Synced Jun 25, 2026, 6:45 AM EDT
Terminated No phase listed Observational

ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain

NCT01834937
View directory record Official record
Conditions
Pain Resulting From Bone Metastases
Interventions
ExAblate MRgFUS (Magnetic Resonance guided Focused Ultrasound Surgery)
Device
Lead sponsor
InSightec
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
6
States / cities
Duarte, California • San Francisco, California • Stanford, California + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2018 · Synced Jun 25, 2026, 6:45 AM EDT
Recruiting Phase 2 Interventional

Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617

NCT06972628
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer, Prostate Cancer Patients With Bone Metastasis, Prostate Cancer (CRPC), Prostate Cancer, Prostate Cancer Metastatic
Interventions
Administering Lutetium-177-PSMA-617 (PLUVICTO)
Drug
Lead sponsor
Ebrahim S Delpassand
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Jun 25, 2026, 6:45 AM EDT
Recruiting Phase 2 Interventional

Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis

NCT06517875
View directory record Official record
Conditions
Primary Myelofibrosis, Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
Interventions
Momelotinib, Luspatercept
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
5
States / cities
Ann Arbor, Michigan • New York, New York • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Jun 25, 2026, 6:45 AM EDT
Active, not recruiting Early Phase 1 Interventional

Gemcitabine Plus Ascorbate for Sarcoma in Adults (Pilot)

NCT04634227
View directory record Official record
Conditions
Sarcoma, Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma, Metastatic Bone Tumor, Bone Sarcoma
Interventions
Ascorbate
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jun 25, 2026, 6:45 AM EDT
Not listed Phase 1 Interventional

A Dose Finding Study to Treat Bone Tumor(s)

NCT06008483
View directory record Official record
Conditions
Bone Cancer, Bone Tumor, Solid Tumor, Metastatic Cancer to the Bone, Metastatic Tumor to the Bone
Interventions
153-Sm-DOTMP (Samarium-153-DOTMP)
Drug
Lead sponsor
QSAM Therapeutics, Inc.
Industry
Eligibility
15 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Chicago, Illinois • Columbia, Missouri • New Brunswick, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Jun 25, 2026, 6:45 AM EDT
Completed No phase listed Observational

Treatment Patterns in Metastatic Prostate Cancer

NCT02729103
View directory record Official record
Conditions
Prostatic Neoplasm
Interventions
Xofigo (Radium 223 dichloride,BAY88-8223)
Drug
Lead sponsor
Bayer
Industry
Eligibility
45 Years and older · Male only
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Jun 25, 2026, 6:45 AM EDT
Withdrawn Phase 1 Interventional

A Dose Finding Study of CycloSam® Combined With External Beam Radiotherapy

NCT03612466
View directory record Official record
Conditions
Osteosarcoma, Bone Metastases
Interventions
153Sm-DOTMP, External beam radiotherapy., Calcium Carbonate, Mozobil, Neupogen Injectable Product
Drug · Radiation
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
15 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Jun 25, 2026, 6:45 AM EDT
Terminated Phase 2 Interventional Results available

Stem Cell Transplantation for Metastatic Solid Tumors

NCT00001880
View directory record Official record
Conditions
Neoplasm Metastasis
Interventions
methotrexate, Cyclosporin
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
10 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Jun 25, 2026, 6:45 AM EDT
Completed Not applicable Interventional

Percutaneous Cryoablation in Treating Patients With Painful Bone Metastases

NCT00608855
View directory record Official record
Conditions
Metastatic Cancer, Pain, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
questionnaire administration, cryosurgery, pain therapy, quality-of-life assessment
Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
10
States / cities
Jacksonville, Florida • Ann Arbor, Michigan • Detroit, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Jun 25, 2026, 6:45 AM EDT
Terminated Phase 2 Interventional

Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer

NCT04754425
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Adenocarcinoma, Metastatic Prostate Small Cell Neuroendocrine Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Biopsy, Biospecimen Collection, Erdafitinib
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Jun 25, 2026, 6:45 AM EDT
Completed Phase 2 Interventional Results available

S0622, Dasatinib in Treating Patients With Stage IV Breast Cancer That Has Spread to the Bone

NCT00410813
View directory record Official record
Conditions
Breast Cancer, Metastatic Cancer
Interventions
dasatinib
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
117
States / cities
Mobile, Alabama • Anchorage, Alaska • Bentonville, Arkansas + 76 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jun 25, 2026, 6:45 AM EDT
Completed Phase 1Phase 2 Interventional Results available

CC-4047 in Treating Patients With Myelofibrosis

NCT00669578
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Secondary Myelofibrosis
Interventions
CC-4047
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 29, 2019 · Synced Jun 25, 2026, 6:45 AM EDT
Completed Phase 1 Interventional

Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy

NCT00005634
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Prostate Cancer, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
vorinostat
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Jun 25, 2026, 6:45 AM EDT
Completed No phase listed Observational

Treatment Patterns in Castrate Resistant Prostate Cancer Patients With Bone Metastases in a Medicare Population

NCT02518698
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radium-223 dichloride (Xofigo, BAY88-8223)
Drug
Lead sponsor
Bayer
Industry
Eligibility
55 Years to 88 Years · Male only
Enrollment
1,163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 17, 2018 · Synced Jun 25, 2026, 6:45 AM EDT
Completed Phase 1Phase 2 Interventional

Effect of Samarium on the Relief of Pain Due to Vertebral Metastases

NCT00374751
View directory record Official record
Conditions
Cancer, Metastasis, Pain
Interventions
Samarium (153SM)
Drug
Lead sponsor
New York Presbyterian Brooklyn Methodist Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Aug 25, 2019 · Synced Jun 25, 2026, 6:45 AM EDT
Completed Phase 4 Interventional

Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis

NCT00035997
View directory record Official record
Conditions
Prostate Cancer
Interventions
Zometa
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
56
States / cities
Birmingham, Alabama • Anchorage, Alaska • Anaheim, California + 50 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2009 · Synced Jun 25, 2026, 6:45 AM EDT
Terminated Phase 2 Interventional

Doxorubicin and Strontium-89 With or Without Celecoxib in Treating Patients With Progressive Androgen-Independent Prostate Cancer and Bone Metastases

NCT00080782
View directory record Official record
Conditions
Metastatic Cancer, Prostate Cancer
Interventions
Celecoxib, Doxorubicin Hydrochloride, Strontium chloride Sr 89
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Jun 25, 2026, 6:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of Metabolic Syndrome in Adolescent and Young Adult Survivors of Childhood Leukemia Who Have Undergone Stem Cell Transplant

NCT00920842
View directory record Official record
Conditions
Cardiovascular Complications, Leukemia, Long-term Effects Secondary to Cancer Therapy in Children, Metabolic Syndrome
Interventions
Not listed
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
9 Years to 21 Years
Enrollment
244 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 2, 2012 · Synced Jun 25, 2026, 6:45 AM EDT
Terminated No phase listed Observational

Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant

NCT00957736
View directory record Official record
Conditions
Cancer
Interventions
polymorphism analysis, laboratory biomarker analysis
Genetic · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
Not listed
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 13, 2013 · Synced Jun 25, 2026, 6:45 AM EDT
Terminated Phase 1 Interventional

HGS-ETR2 to Treat Children With Solid Tumors

NCT00428272
View directory record Official record
Conditions
Ewing's Sarcoma, Osteosarcoma, Neuroblastoma, Rhabdomyosarcoma
Interventions
Lexatumumab alone, Lexatumumab in combination, Interferon gamma 1b in combination, Gamma 1b potential expansion
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 30 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Jun 25, 2026, 6:45 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Palliative Radiation Therapy vs. no Palliative Radiation Therapy for Patients With High Risk Bone Metastases That Are Not Causing Significant Pain

NCT03523351
View directory record Official record
Conditions
Metastatic Solid Tumors of Metastatic Disease
Interventions
Radiation Therapy, Systemic Therapy
Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
9
States / cities
Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2025 · Synced Jun 25, 2026, 6:45 AM EDT
Completed Phase 2 Interventional

Arsenic Trioxide in Treating Patients With Acute Myeloid Leukemia

NCT00005795
View directory record Official record
Conditions
Leukemia
Interventions
arsenic trioxide
Drug
Lead sponsor
Northwestern University
Other
Eligibility
16 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 10, 2012 · Synced Jun 25, 2026, 6:45 AM EDT
Completed Phase 3 Interventional

Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications

NCT00799461
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Atypical Chronic Myeloid Leukemia, BCR-ABL Negative, Blastic Phase Chronic Myelogenous Leukemia, Cancer Survivor, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, de Novo Myelodysplastic Syndromes, Depression, Disseminated Neuroblastoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Fatigue, Long-term Effects Secondary to Cancer Therapy in Adults, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Previously Treated Myelodysplastic Syndromes, Primary Myelofibrosis, Psychosocial Effects of Cancer and Its Treatment, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Splenic Marginal Zone Lymphoma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Small Lymphocytic Lymphoma
Interventions
internet-based intervention, questionnaire administration, psychosocial assessment and care, assessment of therapy complications, management of therapy complications, fatigue assessment and management, counseling intervention
Other · Procedure
Lead sponsor
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Other
Eligibility
18 Years and older
Enrollment
1,337 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 6, 2012 · Synced Jun 25, 2026, 6:45 AM EDT